The customer reported that a patient underwent a red blood cell exchange (rbcx) procedure.After discharge from the unit, the patient fainted on the way home.The patient had some facial bruising and scrapes and was unsure if he hit his head.Patient was seen in the emergency department and received a head ct scan and admitted overnight for observation.Per the customer, the patient completed the procedure with no complications and the patient was observed by the nursing staff for approximately 20 minutes post procedure.The patient is instable condition and did not require follow-up.The disposable kit is not available for return because it was discarded by the customer.This report is being filed due to medical intervention in the form of head ct and overnight hospitalization.
|
Investigation: a review of the device history record (dhr) for this unit showed no irregularities during manufacturing that were relevant to the reaction the patient experienced.The run data file (rdf) was analyzed for this event.Based on the information available in the run data file, the spectra optia system operated as intended.There is no indication in the run data file of a clear root cause for the patient fainting following the procedure.Per the therapeutic apheresis handbook: a physician's reference, 2nd edition, first time procedure patients reactions may occur in approximately 4.8% of procedures, and 1.2% of procedure patients experience reactions to citrate, based on the results of a survey of therapeutic procedures.Of these reactions, most were mild and well tolerated.The spectra optia system has many safety features.However, a patient reaction can occur rapidly.Therefore, it is imperative that the operator continuously monitor the patient and the system throughout the procedure.Root cause: this disposable set was unavailable for specific root cause analysis.Based on information provided by the customer, it is possible that the patient exhibited an allergic reaction to acd-a and/or eto.
|
This record was identified during a retrospective review of mdr's, per fda request, to identify records in which a serious injury or medical intervention occurred, but the type of reportable event was not indicated as a serious injury of the mdr form.This supplement is being filed to modify information per fda request.
|